Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Ramaswamy Govindan Md

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6964-9612; OpenAlex author ID A5068824818. Sources: ClinicalTrials.gov.

Their work

Papers
1
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2016: 1 trial · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 1

  1. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗

Trials 1

  1. MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Principal investigator NCT02669914↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Patrick M. Grierson · 1 shared paper, 2024 · strength 0.15
  2. William G. Hawkins · 1 shared paper, 2024 · strength 0.15
  3. Ashenafi Shiferaw Bulle · 1 shared paper, 2024 · strength 0.15
  4. Vikas Somani · 1 shared paper, 2024 · strength 0.15
  5. Paarth B. Dodhiawala · 1 shared paper, 2024 · strength 0.15
  6. Sapana Bansod · 1 shared paper, 2024 · strength 0.15
  7. Kian‐Huat Lim · 1 shared paper, 2024 · strength 0.15
  8. Li Ding · 1 shared paper, 2024 · strength 0.15
  9. Ryan C Fields · 1 shared paper, 2024 · strength 0.15
  10. Andrea Wang‐Gillam · 1 shared paper, 2024 · strength 0.15
  11. David G DeNardo · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.